Update from the ReIMAGINE Prostate Cancer Screening Study NCT04063566: Inviting Men for Prostate Cancer Screening Using Magnetic Resonance Imaging.
暂无分享,去创建一个
S. Punwani | F. Giganti | C. Moore | M. Emberton | E. Isaac | H. Sidhu | L. Brown | M. van Hemelrijck | A. Santaolalla | T. Coolen | N. Mccartan | C. Moss | A. Haire | D. Kopcke | S. Green | S. Tuck | T. Marsden | J. Hadley | G. Brembilla
[1] T. H. van der Kwast,et al. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. , 2019, European urology.
[2] D. Atkinson,et al. Simplified Luminal Water Imaging for the Detection of Prostate Cancer From Multiecho T2 MR Images , 2018, Journal of magnetic resonance imaging : JMRI.
[3] J. Sterne,et al. Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial , 2018, JAMA.
[4] J. Hugosson,et al. Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality , 2018, Scandinavian journal of urology.
[5] M. Parmar,et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confi rmatory study , 2018 .
[6] J. Gohagan,et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow‐up of 15 years , 2017, Cancer.
[7] Andrew J. Vickers,et al. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring , 2008, Nature Reviews Cancer.
[8] J. Crowley,et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.